S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$64.27
+1.63 (+2.60%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$61.04
$64.42
50-Day Range
$47.96
$74.26
52-Week Range
$40.69
$115.33
Volume
1.38 million shs
Average Volume
1.78 million shs
Market Capitalization
$11.57 billion
P/E Ratio
28.44
Dividend Yield
N/A
Price Target
$96.30

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
49.8% Upside
$96.30 Price Target
Short Interest
Healthy
3.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.64mentions of Catalent in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$31,738 Sold Last Quarter
Proj. Earnings Growth
9.12%
From $2.85 to $3.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

71st out of 1,005 stocks

Pharmaceutical Preparations Industry

24th out of 486 stocks


CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory manag

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Should You Exit Catalent (CTLT)?
Brokerages Set Catalent, Inc. (NYSE:CTLT) PT at $96.30
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Catalent (NYSE:CTLT) Research Coverage Started at StockNews.com
Catalent Shareholder Notice
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Catalent Shareholder Action Reminder
Will Catalent (CTLT) be Able to Provide Long-Term Returns?
Catalent (CTLT) Misses Q2 Earnings Estimates
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
2/07/2023
Today
3/25/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$96.30
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$78.00
Forecasted Upside/Downside
+49.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$503 million
Pretax Margin
10.60%

Debt

Sales & Book Value

Annual Sales
$4.83 billion
Cash Flow
$5.79 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
179,045,000
Market Cap
$11.57 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Alessandro MaselliAlessandro Maselli
    President, Chief Executive Officer & Director
  • Thomas P. CastellanoThomas P. Castellano
    Chief Financial Officer & Senior Vice President
  • Kay SchmidtKay Schmidt
    Senior Vice President-Technical Operations
  • Lim Chin Wei
    Manager-Global Scientific Affairs
  • Julien Meissonnier
    Chief Scientific Officer & Vice President













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

9 brokerages have issued 1-year target prices for Catalent's stock. Their CTLT share price forecasts range from $78.00 to $145.00. On average, they predict the company's share price to reach $96.30 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2023?

Catalent's stock was trading at $45.01 at the beginning of 2023. Since then, CTLT shares have increased by 42.8% and is now trading at $64.27.
View the best growth stocks for 2023 here
.

Are investors shorting Catalent?

Catalent saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 5,240,000 shares, a decline of 20.7% from the January 31st total of 6,610,000 shares. Based on an average trading volume of 2,930,000 shares, the days-to-cover ratio is presently 1.8 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) released its quarterly earnings data on Tuesday, February, 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.64 by $0.02. The company earned $1.15 billion during the quarter, compared to the consensus estimate of $1.12 billion. Catalent had a trailing twelve-month return on equity of 11.40% and a net margin of 8.62%.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of $3.13-$3.54 for the period, compared to the consensus earnings per share estimate of $3.20. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $4.69 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of institutional and retail investors. Top institutional investors include T. Rowe Price Investment Management Inc. (9.21%), Veritas Asset Management LLP (6.21%), Artisan Partners Limited Partnership (4.35%), American Century Companies Inc. (2.30%), Geode Capital Management LLC (2.01%) and Franklin Resources Inc. (1.84%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $64.27.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $11.57 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 3/26/2023 by MarketBeat.com Staff